COMMUNIQUÉS West-GlobeNewswire

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties
31/03/2025
WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has entered into a royalty purchase agreement with an entity that [...]
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
31/03/2025
-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron ® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial - - Halneuron ® CINP P2b study interim data readout is expected in Q4 2025 - - [...]
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
31/03/2025
SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies [...]
IBA – ACQUISITION OF OWN SHARES
31/03/2025
Immediate Release – March 31 st , 2025 Louvain-la-Neuve, Belgium, March 31 st , 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion [...]
IBA – ACQUISITION D’ACTIONS PROPRES
31/03/2025
Publication immédiate – 31 mars 2025 Louvain-la-Neuve, Belgique, 31 mars 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam [...]
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
31/03/2025
More than 92% of schizophrenia patients taking TEV- ' 749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1 New data from UZEDY ® (risperidone) [...]
CORRECTION - Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2024
31/03/2025
The Company Reports Continued Growth in Annual Revenue PLAINVIEW, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Please note that, in a release issued under the same headline earlier today by Vaso Corporation (OTCQX: VASO), [...]
Radiance Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of RB-164™, an ROR-1 Targeted ADC, for Hematologic and Solid Malignancies
31/03/2025
BOSTON, Mass, March 31, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today announced that the U [...]
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
31/03/2025
MEDIA RELEASE NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and [...]
PracticeLink Announces New “First Practice Fund” Scholarship to Support Physicians
31/03/2025
ST. LOUIS and HINTON, West Virginia, March 31, 2025 (GLOBE NEWSWIRE) -- PracticeLink , the nation’s most trusted physician recruitment resource and home of the most widely used online physician job board, announces its [...]
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
31/03/2025
Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK ® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic [...]
Zelluna ASA [ZLNA]: Registration of reverse share split
31/03/2025
Oslo, Norway, 31 March, 2025 Reference is made to the stock exchange notice published by the Zelluna ASA (the " Company ") on 27 March 2025 with key information concerning a reverse share split in the ratio of 10:1. The [...]
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast
31/03/2025
Episode titled "From Medicine to Biotech Innovation" now available PITTSBURGH, March 31, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage [...]
CLJA Veterans: Is Uncle Sam’s Marker Still Good on PACT Act EO Claims
31/03/2025
MURPHYSBORO, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Last week Congressman Mike Bost chaired the House Committee on Veterans’ Affairs on hearings raised by the subcommittees on Technology Modernization, Disability [...]
Elite Equine Health and Performance Introduces Ulcer Defense: A Revolutionary Natural Solution for Equine Gastric Ulcers
31/03/2025
Challenging Conventional Wisdom in Equine Health Seligman, Az, March 31, 2025 (GLOBE NEWSWIRE) -- Elite Equine Health & Performance (EEHP) is proud to introduce Ulcer Defense , a groundbreaking, all-natural [...]
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
31/03/2025
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysis This profound treatment [...]
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
31/03/2025
TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at [...]
Apothecare and Stok’d Cannabis Announce Partnership to Provide Cannabis Consultations for Customers
31/03/2025
TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Apothecare, a pharmacist-led cannabis consultation service, is collaborating with a growing network of trusted cannabis retailers—including Stok’d Cannabis, one of Ontario’s [...]
Polyrizon Ltd. Announces $17.0 Million Private Placement
31/03/2025
RAANANA, ISRAEL, March 31, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into definitive [...]

Pages